Hanbon Technology (688755): Won the procurement project of North China Pharmaceutical Group New Drug Research and Development Co., Ltd., with a bid amount of 1.03 million yuan
I'm LongbridgeAI, I can summarize articles.Hanbon Technology (688755) won the bid for the procurement project of North China Pharmaceutical Group New Drug Research and Development Co., Ltd., with an amount of 1.03 million yuan. The company's operating income for 2025 is 735 million yuan, and the net profit is 60 million yuan. In the first quarter of 2026, the operating income is 195 million yuan, and the net profit is 18 million yuan
According to Tongbi Finance, data from Qichacha shows that, based on the "Procurement Announcement for Equipment Chromatography System by North China Pharmaceutical Group New Drug Research and Development Co., Ltd.", Jiangsu Hanbon Technology Co., Ltd. announced on May 25, 2026, that it won the bid for the procurement project of North China Pharmaceutical Group New Drug Research and Development Co., Ltd., with a bid amount of 1.03 million yuan.
Related listed company: Hanbon Technology (688755.SH)
Tongbi Finance Tip:
Hanbon Technology (688755.SH) had an operating income of 735 million yuan in 2025, with an operating income growth rate of 6.40%. The net profit attributable to the parent company was 60 million yuan, with a net profit growth rate of -24.81%, and a return on net assets of 5.80%.
In the first quarter of 2026, the company's operating income was 195 million yuan, with an operating income growth rate of 17.80%. The net profit attributable to the parent company was 18 million yuan, with a net profit growth rate of 66.22%.
Currently, the company belongs to the industrial sector, with the main product types being specialized equipment and components. The 2025 report shows the main composition of its business as small molecule drug separation and purification equipment: 69.26%; large molecule drug separation and purification equipment: 23.84%; others: 6.88%; other businesses: 0.03%.